A physician's guide to azathioprine metabolite testing

Gastroenterology and Hepatology

Volumn 2, Issue 1, 2006, Pages 58-63

  Cuffari, Carmen ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

6 mercaptopurine; Azathioprine; IBD; Metabolites; Therapy

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ALLERGIC REACTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; CYTOTOXICITY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; GENETIC POLYMORPHISM; HEPATITIS; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; PANCREATITIS; PHYSICIAN; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 33845980547     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab. 2002;3:275-287.
2. Weinshilboum RN, Sladek SI. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyl transferase activity. Am J Hum Genet. 1980;32:651-662.
3. Christie NT, Drake S, Meyn RE. 6-thioguanine induced DNA damage as a determinant of cytotoxicity in cultured hamster ovary cells. Cancer Res. 1986;44:3665-3671.
4. Fairchild C-R, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breaks in response to 6-thioguanine treatment. Biochem Pharmacol. 1986;35:3533-3541.
5. Lennard L. The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Eur J Clin Pharmacol. 1992;43:329-339.
6. Alves S, Prata MJ, Ferreira F, Amorim A. Screening of thiopurine methyl S-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Human Mutat. 2000;15:246-253.
7. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirements in a thiopurine methyltransferase deficient child with acute lymphoblastic leukemia. J Pediatr. 1991;119:985-989.
8. Bostrom B, Erdman G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993;15:80-86.
9. Lennard L, Rees CA, Lilleyman JS, et al. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1993:16:359-363.
10. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered. N Engl J Med. 1983;308:1005-1009.
11. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85:1897-7-1902.
12. Kombluth A, Sachar DB, Salomon P. Crohn's disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Diseases. Philadelphia, Pa: WB Saunders;1998:1708-1734.
13. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 1995;122:132-142.
14. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993;105:367-372.
15. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991;101:39-46.
16. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol. 1993;88:1198-1205.
17. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
18. Colonna T, Korelitz BI. The role of leukopenia in 6-mercaptopurine- induced remission of refractory Crohn's disease. Am J Gastroenterol. 1993;89:362-366.
19. Brogan M, Hiserot J, Olicet M. The effects of 6-mercaptopurine on natural killer cell activities in Crohn's disease. J Clin Immunol. 1985;5:204-211.
20. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med. 1995;111:641-649.
21. Cuffari C, Theoret Y, Latour S, et al. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39:401-406.
22. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
23. Gupta P, Gokhlae R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:450-454.
24. Belaiche J, Desager JP, Horsman Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol. 2001;36:71-76.
25. Cuffari C, Hunt S, Bayless TM. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize therapy in IBD. Gut. 2001;48:642-646.
26. Achar JP, Stevens T, Brzezinski A, Seidner D, Lashner B. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopruine and azathioprine therapy. Am J Gastroenterol. 2000;95:A272.
27. Lowry PW, Franklin CL, Weaver AL, et al. Leukopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut. 2001;49:656-664.
28. Goldenberg BA, Rawsthorne P, Berstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99:1744-1748.
29. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
30. Bo J, Schroder H, Kristinsoon J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 1999;86:1080-1086.
31. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14:567-572.
32. Black AJ, McLeod HL, Capell HA. Thiopurine methyl transferase predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-718.
33. Szumlanski C, Weinshilboum RN. Sulphasalazine inhibition of thio methyl transferase: possible mechanism of interaction with 6-mercaptopurine. Br J Clin Pharmacol. 1995;39:456-459.
34. Proujansky R, Maxwell M, Johnson J, et al. Molecular genotyping predicts complications of 6-mercaptopurine therapy in childhood IBD. Gastroenterology. 1999;116:A800.
35. Cuffari C, Dassoupolus T, Bayless TM. Thiopurine methyl-transferase activity influences clinical response to azathioprine therapy in patients with IBD. Clin Gastroenterol Hepatol. 2004;2:410-417.
36. Kaskas BA, Louis E, Hinderof U, et al. Safe treatment of thiopurine S-transferase deficient Crohn's disease patients with azathioprine. Gut. 2003;52:140-142.
37. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7:1816-1823.
38. Sandborn WJ, Tremaine WJ, Wolfe DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 1999;117:527-535.
39. Garza A, Sninsky CA. Changes in red cell mean corpuscular volume (MCV) during azathioprine or 6-mercaptopurine therapy for Crohn's disease may indicate optimal dose titration. Gastroenterology. 2001;120:A3166.